Also known as: Liver Bioregulator, Ovagen Khavinson Peptide
Half-life: Short (minutes); biological effect persists via gene-expression modulation
Last reviewed: · Published:
Ovagen is a short peptide bioregulator from the Khavinson family, designed for hepatic (liver) applications. It is proposed to target hepatocyte gene expression to support liver detoxification function, restore age-related hepatic decline, and aid recovery from toxic or viral liver injury. Despite the name (which is morphologically similar to ovarian peptides), Ovagen is a liver-targeting compound in the Khavinson nomenclature.
Russian clinical-observational studies have evaluated Ovagen in chronic hepatitis (especially viral), drug-induced and toxic hepatitis, fatty liver disease, and age-related decline in hepatic function. Reported outcomes have included normalization of liver enzymes (ALT, AST), improvements in synthetic liver function markers, and subjective improvement in symptoms associated with chronic liver disease.
Ovagen is sold by research-chemical vendors outside Russia. Western clinical validation is essentially absent. The compound is sometimes considered alongside other hepatic-support agents (silymarin, S-adenosylmethionine) but the evidence base for Ovagen is much thinner outside Russian observational reports.
Ovagen was developed in the 2000s as part of the Khavinson short-peptide bioregulator program, specifically for hepatic applications. The compound entered Russian clinical observational use in hepatology contexts through the 2000s and 2010s.
Russian clinical use in hepatology populations has reported good tolerability. Western safety validation is essentially absent. The compound is not a substitute for proven antiviral therapies in viral hepatitis (where direct-acting antivirals are curative for hepatitis C and effectively manage hepatitis B) and self-experimentation in patients with significant liver disease without physician supervision is inappropriate.
Dose Range
1-5 mg
Frequency
Once daily (SubQ) or sublingual
Duration
10-20 day cycles, repeated 2-3 times per year
Dosing information is for educational purposes only. Consult a healthcare professional before using any peptide.
Typical Vial Size
20 mg
Water Type
Bacteriostatic water (BAC water)
Mixing Volume
2 mL
Half-Life
Short (minutes); biological effect persists via gene-expression modulation
Molecular Weight
~400-600 Da
Store reconstituted vial refrigerated at 2-8°C. Use within 21-30 days. Sublingual or subcutaneous administration is typical.
FDA Status
Not FDA approved.
Legal Status
Unregulated research chemical outside Russia.
USA
Not approvedResearch-only
EU
Not approvedNot authorized as medicinal product
UK
Not approvedClassified as research chemical
Russia
Used in clinical practiceUsed as bioregulator in Russian hepatology
Australia
Not approvedTGA has not evaluated
Canada
Not approvedNot authorized for human use
Khavinson VK, Kuznik BI, Tarnovskaya SI, Linkova NS
Bulletin of Experimental Biology and Medicine (2015)
Foundational Khavinson-group review covering the broader short-peptide bioregulator family including Ovagen.
View Study →Khavinson VK, Anisimov VN, Linkova NS, Bakhmet AA
Bulletin of Experimental Biology and Medicine (2020)
Modern Khavinson-group mechanistic review applicable to all tissue-targeting bioregulators including Ovagen.
View Study →Khavinson VK, Korkushko OV, Kuznik BI
Bulletin of Experimental Biology and Medicine (2013)
Russian-group review of peptide bioregulators in hepatology contexts including the rationale and observational data underlying Ovagen's clinical applications.
View Study →Khavinson short peptide bioregulator targeting pancreatic tissue and glucose metabolism.
Khavinson short peptide bioregulator targeting thymus / immune cells.
Khavinson short peptide bioregulator targeting cardiac muscle and vascular endothelium.
Track Ovagen and more with PinnyPeptide.
Sign Up to Track OvagenFree forever · defaults pre-filled from this article